Iovance publishes corporate presentation on TIL cell therapy platform, Amtagvi launch and pipeline updates
PUBT · 4d ago
Share
Listen to the news
- Iovance outlined FY 2026 revenue guidance of $350 million-$370 million, citing about 45% year-over-year quarterly revenue growth.
- Q2 2026 revenue guidance set at $86 million-$88 million; cash reported at about $319 million as of March 31, 2026.
- Amtagvi performance highlighted with 31.4% ORR, 36.5-month median duration of response, 19.7% five-year overall survival, 13.9-month median OS.
- Real-world Amtagvi data showed 44% ORR overall; 52% ORR in patients with two or fewer prior therapy lines.
- Pipeline focus on lifileucel expansion, including TILVANCE-301 in frontline melanoma, IOV-LUN-202 in post-anti-PD-1 NSCLC with potential 2H27 launch.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief on June 30, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved